Clinical Trial Detail

NCT ID NCT03257163
Title Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

gastric adenocarcinoma

Therapies

Capecitabine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.